Shots: Taking Doxy-PEP After Sexual Activity May Offer Protection Against Certain STDs

Scientists have made a groundbreaking discovery regarding the antibiotic doxycycline and its ability to prevent sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis. This new prevention tool, known as doxy-PEP, involves taking a dose of doxycycline in the hours immediately after engaging in sexual activity to eliminate the STI before symptoms develop or it spreads to others. Extensive research has shown that doxy-PEP significantly reduces the risk of contracting these common bacterial STIs. In light of these findings, the Centers for Disease Control and Prevention (CDC) plans to release guidance to ensure this preventative treatment is available to doctors and public health departments. It is important to note that while doxy-PEP may not be recommended for everyone, especially women, and close monitoring of antibiotic resistance is necessary, experts emphasize the potential of this treatment in curbing the increasing rates of STIs. Dr. Edward Hook, a professor at the University Alabama, Birmingham, states, “It’s time to do something different” as previous efforts to control STIs have not been successful. Research primarily focusing on gay and bisexual men, as well as transgender women, has demonstrated the effectiveness of doxy-PEP in reducing the incidence of STIs. Dr. Annie Luetkemeyer, a professor at the University of California, San Francisco, who led a clinical trial on doxy-PEP, reports consistent reductions in STIs, affirming its safety and efficacy. Luetkemeyer’s study, published in the New England Journal of Medicine, found an overall reduction of 65% in new STIs among those who took doxycycline within 24 to 72 hours after engaging in unprotected sex. It specifically reduced new cases of chlamydia by approximately 80% and gonorrhea by over 50%. Although there were fewer cases of syphilis in their trial, it also showed a reduction in its incidence. The trial was prematurely halted to allow the control group, who did not receive the antibiotic, to begin treatment due to its proven effectiveness. While these studies provide hope, there is a need for further research to determine the efficacy of doxy-PEP for most women. Though a recent trial conducted in Kenya did not show reductions in STIs among women, more studies are required before concluding that doxy-PEP is ineffective for this group. The potential contribution of doxy-PEP to antibiotic resistance is a concern that needs to be addressed. Therefore, careful monitoring is necessary to ensure minimal resistance and to combat the global crisis of antibiotic resistance. Researchers have already observed an 8% increase in resistance levels of Staphylococcus aureus, a bacteria commonly found on the nose and skin, among those taking doxy-PEP. However, this antibiotic-resistant strain is not typically treated with doxycycline. Further precautions need to be taken, especially in relation to the antibiotic resistance of gonorrhea, which already exhibits resistance to the antibiotics that doxycycline belongs to. Despite these concerns, doxy-PEP remains a valuable tool in the fight against STIs. By expanding access to this preventative treatment, the rising rates of STIs can be addressed. The anticipated federal guidelines, along with growing evidence supporting doxy-PEP, will pave the way for mainstream adoption in STI prevention and LGBTQ+ healthcare. While it is important to weigh the risks of increased antibiotic resistance, using doxy-PEP is not a choice between no antibiotics and antibiotics, as those who did not receive the treatment in Luetkemeyer’s study ultimately required antibiotics for STI treatment. In conclusion, doxy-PEP shows promise in preventing the spread of STIs and offers hope for a more effective approach to STI control.

 

Reference

Denial of responsibility! SamacharCentrl is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Denial of responsibility! Samachar Central is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
DMCA compliant image

Leave a Comment